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S210 Poster Session IConclusions:Near 50% of patients with refractory or relapsed HD
can be successfully treated with high dose chemotherapy and autol-
ogous stem cell transplantation.
It is important to have a longer follow up on these patients so we
can perform analysis on prognostic factors for relapse and survival.140
EVALUATING EFFECTIVENESS OF CHANGING THE ADMINISTRATION
TIME OF PLERIXAFOR ON PERIPHERAL CD 34 + CELL COUNTS
Johnson, M., Sirilla, J., Elder, P. OSU Medical Center-James Cancer
Hospital, Columbus, OH
Plerixafor has been shown to rapidly increase CD 34+ cells in
healthy volunteers alone or in combination with Neupogen (Fowler,
et al, 2009). The addition of Plerixafor to Neupogen results in a tri-
pling of circulating CD34+ cells 10 hours after administration
(Clerq, 2009).
At TheOhio State UniversityMedical Center-James CancerHos-
pital, we initially administered Plerixafor at 10 p.m. (10 hours prior
to the start of Apheresis). Administering Plerixafor at this time cre-
ated some issues requiring attention. First, there is the issue of incon-
venience to the patient. The patient would come to the hospital at
9:45 p.m., get their dose, go home or to a local hotel, then return
to the hospital for Apheresis at 7:30 a.m. the followingmorning. Sec-
ondly, because the outpatient clinic closed at 5:00 p.m., the patient
would go to the inpatient unit and have the charge nurse administer
the Plerixafor. At times, the inpatient unit had no available rooms to
see the patient and observe for side effects, becoming a concern for
the inpatient nursing staff to monitor the patient appropriately. Be-
cause of these issues, our institution changed the administration time
of Plerixafor to 6:15 p.m. The outpatient clinic adjusted their clinic
hours to accommodate the need for patients receiving Plerixafor.
Currently, we have administered Plerixafor to 24 patients (2 pa-
tients were remobilized with Plerixafor) since the drug received
FDA approval in December, 2008. Nineteen patient received Plerix-
afor at 10 p.m. Of these, sixteen patients had an adequate peripheral
CD 34+ count (.10) allowing them to collect an adequate amount of
stem cells for transplant. Of the 5 patients that received Plerixafor at
6:15 p.m., 4 patients had an adequate peripheral CD 34+ cell count
to proceed to Apheresis.
Changing the time of Plerixafor to 6:15 p.m. aided in the overall
safety of the patient. It is less inconvenient for the patient to return
to the hospital in the early evening (during daylight hours) and it al-
lows for the outpatient nursing staff to address any issues in an appro-
priate setting.
Our institution is looking at other areas of improvement using
Plerixafor. We are currently using an algorithm in determining
which patients may not mobilize an adequate number of CD 34+
cells. Also, we are checking the peripheral CD 34+ cell count on
day 4 of Neupogen in patients that are coming to the hospital to
have their central line placed to assess the need for Plerixafor that
evening.141
NEED OF RECONSIDERATION OF MOBILIZATION STRATEGY IN AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: RE-
SULTS OF THE POSITIVE IMPACT OF HIGH NUMBER OF
CD34 + INFUSED CELLS
Michallet, M.1, Sobh, M.1, Nicolini, F.E.1, Raus, N.1, Baracco, F.1,
Cannas, G.1, Chelghoum, Y.1, Clapisson, G.1, Thomas, X.1, Troncy, J.1,
Ducastelle, S.1 1Edouard Herriot Hospital, Lyon, France
This study concerned 130 MM patients who underwent ASCT in
our center between years 2000 and 2007. There were 79males and 51
females with a median age of 56.8 years (34-72). Before transplanta-
tion, all patients received granulocyte-colony stimulating factor (G-
CSF) 5mg/kg/day, PBSC were mobilized in steady state in 135 cases,
62 after G-CSF + cyclophosphamide. As conditioning, all pts re-
ceived melphalan alone with a median total dose of 304 mg (130-
440). Sixty six patients received a single ASCT and 64 patients re-
ceived 2 ASCT in a double ASCT program. After transplantation,there were 2 graft failure, 40% of patients received red blood cell
(RBC) transfusions (median number: 0 [0-23]), and 64% received
platelet transfusions (median number: 1 [0-20]). Themedian number
of days with neutrophils\0.5 G/L was 6 (0-33) and with platelets
\20 G/L was 17 (2-104). The median length of hospitalization for
auto transplantation was 18 days (14-54). To assess the impact of
the infused CD34+ cells number, we have analyzed 2 groups: group
1 (n5 86) for ASCT with a number of CD34 +#3106/kg and
group 2 (n5 107) for ASCT with a number of CD34 +.3106/kg.
Results:We found a high significant impact of the high number of
infused CD34+(group 2) on platelets recovery (p5 0.002). The uni-
variate analysis using Cox model, showed a trend for the high num-
ber of infused CD34+ cells (group2) on leukocyte recovery
O.R5 0.748 [0.5-1.0] (p5 0.0568) and a high significant impact of
the same group on neutrophils recovery O.R5 0.670 [0.5-0.9]
(p5 0.009). These results were not changed even after adjustment
on age also on the sequential number of the ASCT in the double
auto ASCT program. The multivariate analysis using Cox model,
studying the impact of CD34+ group, age, gender, poor prognostic
factors [high level of b2microglobulin and del(13)], mobilization
(G-CSF alone or G-CSF + cyclophsphamide), showed a significant
impact only of poor prognostic factors on overall survival
O.R.5 7.94 [1.0-59.2] (p5 0.04) and also on progression free sur-
vival (PFS) O.R.5 2.55 [1.1-5.7] (p5 0.024).
Conclusion:High level of infused CD34+ appeared to be very opti-
mal for hematological recovery after ATSC inMM, without any sig-
nificant impact on O.S and PFS. An economical study is running on
this population to assess the impact of this level on hospitalization
and treatment costs, results will communicated in the future142
REVIEWING THE STATUS OF BACKUP HEMATOPOIETIC STEM CELLS
(HSC) BANKING FOR MULTIPLE MYELOMA (MM) PATIENTS WHO ARE
ELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANS-
PLANT (AHSCT) IN THIS POOR ECONOMY
Abidi, M.H.1,2, Woldie, I.L.1, Goveas, R.1, Ratanatharathorn, V.1,2, Al-
Kadhimi, Z.1,2, Abrams, J.1,2, Ayash, L.1,2, Lum, L.1,2, Uberti, J.1,2
1Wayne State University, Detroit, MI; 2Karmanos Cancer Center, De-
troit, MI
Novel drugs combinations have demonstrated response rates
similar to AHSCT. Due to lack of long term follow up, impact
of these novel agents on HSC mobilization is unknown. AHSCT
is still standard therapy for newly diagnosed MM. There are ran-
domized trials underway to better define the role and timing of
AHSCT in MM. Due to this uncertainty with novel agents, arbi-
trary recommendations are made to cryopreserve backup stem
cells for pts who want to postpone AHSCT & to collect addi-
tional HSC at 1st HSC collection for future use. There is no con-
sensus on minimum duration of HSC cryopreservation, and this
can create significant financial,legal & logistical issues for stem
cell laboratories.
Methods: From 03/2000 to 06/2009, 270 MM pts were evaluated
for AHSCT at Karmanos Cancer Center, Detroit, MI. This review
was conducted to determine utilization of cryopreserved HSC for
a 2nd AHSCT at relapse/progression. No stem cells were collected
if the intent was not to offer AHSCT. Storage time was calculated as
the time between 1st & 2nd BMTs; as time between BMT&death&
as time between BMT & last follow-up for those known to be alive.
Results: Two hundred and fifty two eligible pts had HSC stored
with the intent to immediately proceedwith at least a single AHSCT.
Seventeen pts (6.7%) received a 2nd transplant with progressive dis-
ease as the most common reason, tandem transplant and refractory
disease being other causes to perform delayed AHSCT. Significantly
more men than women received a second transplant. Differences in
age, race and stage of disease were not statistically significant. The
median CD 34+ cells dose collected was 8106/kg. A median 4.9
x106 CD 34+ cells/kg were infused; 26% (66/252) of pts had no cells
remaining after 1st transplant. Five (29%) of the 2nd transplants
were done during the 6months following the first transplant. The re-
mainder occurred between 51 and 92 months following first trans-
plant.
Poster Session I S211At 7 years, the cumulative proportion of those receiving 2nd trans-
plants is 40% (95% CI: 23%, 61%) It should be noted that median
follow-up time for those who have not yet received a second trans-
plant is only 14 months and 75% of these pts have been followed
for 32 months or less. Thus, in a more mature database with longer
follow-up the proportion of those receiving a second transplant may
increase.
Conclusion: We need guidelines for cryopreservation of HSC for
MM pts based on prospective evaluation to best utilize stem cell lab-
oratory resources.
Table 1. Demographic and Disease Characteristics
Cryopreserved HSC UsedAnalysis Results
Median (Range):
Independent variable
Starting TNC
MNC content
Starting CD341Ce
Starting CD31Cell
Hrs from Collection
TNC/mLM
8.
76
lls 5.
s 1.
23
#5
EDIAN (RANGE) U
0E10 (9.5E9 -1.2E11) 0
.3% (26.3 -92.1%) N
5E8 (1.1E8 -2.6E9) \
7E10 (3.6E9-4.2E10) N
(4 -55) N
4E8 vs .4E8 0Yes No
Yes5 17 No5 235 SignificanceAge (Mean, SEM) 54 (1.8) 57 (0.6) 0.25
Race 0.35Black 3 (18%) 75 (32%)
White 14 (82%) 155 (66%)
Other 0 (–) 5 (2%)Gender 0.005
Female 2 (12%) 107 (46%)
Male 15 (88%) 128 (54%)Stage* 0.49
I 0 22 (9%)
II 8 (47%) 51 (22%)
III 9 (53%) 161 (69%)* Durie Salmon Staging SystemGRAFT PROCESSING
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FACTORS AFFECTING CD34 + CELL PURITY, CD34 + CELL RECOVERY,
AND LOG T CELL DEPLETION OF PRODUCTS PROCESSED FOR CD34-EN-
RICHMENT ON THE ISOLEX— CELL SEPARATION DEVICE. A SINGLE CEN-
TER EXPERIENCE
Keever-Taylor, C.A.1, Zhang, L.2, Konings, S.1, Skonecki, J.A.1,
Zheng, H.1, Heidtke, S.A.1 1Medical College of Wisconsin, Milwaukee,
WI; 2Emmes Corporation, Rockville, MD
CD34-enrichment is commonly used as a method for the rigorous
removal of T cells from products used for hematopoietic progenitor
cell transplantation. Published reports have consistently shown
a high level of T cell depletion (TCD) and a high degree of purity
in the CD34-enriched products. Recovery of CD34+ cells from the
starting fraction has been more variable both within and between
centers. We performed univariate (UV) and multi-variable analysis
(MV) of 106 enrichment procedures of products obtained from 59
allogeneic donors to determine factors affecting CD34+ cell recov-
ery, log TCD, and product purity. Variables assessed included: the
number and concentration of total nucleated cells (TNC) loaded
onto the column, starting mononuclear cell (MNC) content, the
number of starting CD34+ and CD3+ cells, and time from the end
of collection to the start of selection. The analysis used a mixedCD341Cell Re
3.9% (18.3-96.1%)
V M
.0007 -
S -
0.0001 \
S -
S -
.0001 0effect model to adjust for multiple observations from the same do-
nors. Factors found to be associated with better CD34+ cell recov-
ery in the UV included fewer starting TNC, loading concentration
#4.0E8 TNC/mL, and fewer starting CD34+ cells. Using back-
ward selection, in the MV only starting CD34+ cells and TNC/
mL remained independently associated with recovery. Indeed, me-
dian CD34+ cell recovery was 63.5% at the lowest quartile of
starting CD34+ cell numbers (1.1E8 -3.6E8) and fell progressively
to 56.5% (3.7E8-5.4E8), 55.0% (5.5E8-7.3E8), and 42.9% (7.5E8-
2.6E9) for the 2nd, 3rd, and 4th quartiles, respectively. The addi-
tional effect of TNC/mL was seen regardless of time from collec-
tion to start of selection and there was no association of TNC/mL
and starting or ending product viability. CD34+ cell purity was
greatest at higher starting numbers of TNC and CD34+ cells
and at lower MNC content. Here a median CD34+ cell purity
of 93.4% was seen for the lowest quartile of starting CD34+ cells
versus 98.6% for the highest quartile. Starting CD34+ cells was
the only variable affecting Log TCD (poorer TCD with more
starting CD34+ cells). In conclusion, CD34+ cell recovery using
the Isolex device can be maximized by restricting the number of
CD34+ cells loaded onto the column and by ensuring that the
TNC loaded are # 4.0E8 TNC/mL. Even though fewer starting
CD34+ cells may result in somewhat poorer final product purity,
T cell content in the final product was not increased.144
A COMPARISON OF IN-SITU CB COLLECTION: VAGINAL VS. CESAREAN
SECTION
Miller, S.1, Kuenne, S.1, Zarlengo, G.2, Stark, C.2, Quinones, R.1,
Freed, B.1 1UC Denver – ClinImmune Labs, Aurora, CO; 2Exempla
St. Joseph Hospital, Denver, CO
With a national cesarean birth rate of .30%, these deliveries
represent a significant source of umbilical cord blood. We there-
fore compared cord blood units (CBU) obtained from planned
cesarean (n5 104) and vaginal (n5 581) births at the same hos-
pital over a seven month period in 2009. In both cases, the CBU
were collected in situ, prior to delivery or removal of the pla-
centa. The cesarean collections were performed with a sterile
connecting device placed within the sterile field connected to
the CB collection bag outside the field. The mean volume and
total nucleated cell count of cesarean CBU (120 ml; 1.4  109
TNC) were 33% greater than vaginal CBU (90 ml; 0.9  109
TNC; p\0.0001). In addition, cesarean CBU had a 0% contam-
ination rate, compared to 7% for vaginal CBU. CD34+ cell
counts were only performed on those CBU that contained
.0.9  109 TNC; the post-processing CD34 counts were not
significantly different between cesarean (4.9  106) and vaginal
births (5.1  106). Deferrals for donor ineligibility and maternal
risks were only 5% in cesarean collections, compared to 11% of
vaginal cord blood donors. There were no safety issues identified
for mothers or babies with the cesarean collections. As a result of
the higher cord blood volume, lower contamination rates, and
fewer deferrals, cesarean collections resulted in a 78% increase
in banking efficiency. This study suggests that cesarean birthsDependent Variable
covery CD341Cell purity Log TCD
97.6%
(69.9-99.4%)
4.3 (3.5-5.0)
V UV MV UV MV
\0.0001 0.005 NS -
0.042 0.017 NS -
0.0001 \0.0001 \0.0001 0.015 0.015
NS - NS -
NS - NS -
.018 0.0002 - NS -
